Study Details

Back to Search Results

A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who showed benefit from prior exposure to MDV3100

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01534052

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-0121

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Oct 2011 - Apr 2017

Masking

None (Open Label)

Enrollment number

52

A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects with Prostate Cancer Who Showed Benefit from Prior Exposure to MDV3100

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who showed benefit from prior exposure to MDV3100? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US105

Pittsburgh, United States, 15215

Site ZA2702

Port Elizabeth, South Africa, 6001

Site US106

San Antonio, United States, 78253

Site US104

Chicago, United States, 60637

Site ZA2701

George, South Africa, 6529

Site MD37301

Chisinau, Republic of Moldova

Site US107

Aurora, United States, 80045

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo